Dr. Tzann Fang (pronounced “Fong”), our new medical oncologist, was born and raised in Taiwan in his hometown of Hsin-chu, which is famous for its high tech industry, named as “the silicon valley of Taiwan.” 

Dr. Fang graduated from China Medical University in Tai-chung, Taiwan. He came to the States and attended graduate school at the University of Wisconsin-Madison. He got a master’s degree in pathology and also did additional cancer research at the Department of Human Oncology at UW-Madison. Dr. Fang completed his internship and residency in internal medicine at the University of Southern Florida in Tampa. He subsequently underwent fellowship in hematology, medical oncology, and bone marrow transplantation at H. Lee Moffitt Cancer Center, a National Cancer Institute-designated comprehensive cancer center in Tampa, Florida.  He then went to Fred Hutchinson Cancer Research Center in Seattle for additional bone marrow transplantation fellowship.

At the University of Florida in Jacksonville, he was appointed as assistant professor and faculty physician in medical oncology, hematology and director of bone marrow transplantation. Most recently, Dr. Fang worked at Presbyterian Intercommunity Hospital in Whittier, California, as a staff physician in hematology and medical oncology.

Dr. Fang had previously worked with Dr. Brad Kramer, Radiation Oncologist at Sky Lakes Medical Center, in Northern Illinois. Both of them share a very similar philosophy and ideas regarding cancer treatment and patient care.  After interviewing for the job, Dr. Fang said he was impressed by the very talented medical staff, who are all highly motivated and strive for the best quality of cancer care.

Dr. Fang and his wife, Sou-may, relocated from Southern California to Klamath Falls. Sou-may has a personal interest in investment, reading and traveling. Dr. and Mrs. Fang  enjoy living in scenic Southern Oregon.

Dr. Fang’s professional interest is in patient cancer care, especially in new developments in cancer treatment. He states, “in the past two decades, due to biotechnology improvements, we have a better understanding of cancer pathogenesis and due to the advancement of biotechnology, more drugs have been transferred from lab bench research to the clinical use. This new category of medication so called ‘target specific’ cancer treatment is not the same as conventional treatment of chemotherapy. The target-specific medications have fewer side effects such as hair loss, nausea and vomiting, bone marrow suppression, mouth soreness, diarrhea or vital organ dysfunction.”